OBJECTIVES: Heart transplantation is the standard treatment in end-stage heart failure and at shortage of cardiac allografts is its major limiting factor. Striving to optimize the use of this limited resource, the aspect that long distance procurement may increase the available donor pool must be taken into consideration. As poly(ADP-ribose)polymerase (PARP)-activation has been identified as a key pathway of reperfusion injury, we assessed the hypothesis that its inhibition would allow an extension of cold preservation time and protect the graft against ischaemia/reperfusion injury.
INTRODUCTION
Heart transplantation still remains the gold standard therapy of end-stage heart failure. However, global myocardial ischaemia/ reperfusion (I/R) injury is an unavoidable limitation that occurs during cardiac surgery, and is a major contributor to early graft failures and a lower long-term survival rate of the recipient [1] . The underlying mechanisms of ischaemic damage and hypoxia include the release of proinflammatory mediators such as reactive oxygen species (ROS), cytokines and chemokines, which lead to adenosine triphosphate (ATP) depletion. Paradoxically, when a donor heart is reperfused following a period of ischaemic cold crystalloid storage, the ischaemic myocardium is acutely subjected to additional tissue damage including intracellular calcium overload, energy depletion, acidosis, activation of granulocytes and the generation of ROS, thus inducing organ dysfunction [2] . At the present, clinical therapies to reduce myocardial reperfusion injury are lacking. Different myocardial preservation solutions are used for cold storage in routine clinical practice including Bretschneider's histidine-tryptophanketoglutarate (Custodiol), Celsior, St Thomas and University of †The first two authors contributed equally to this study.
Wisconsin solution. Although, 4 h has been proven to be a clinically safe ischaemic time regarding graft survival rates [3, 4] , the aforementioned solutions do not completely prevent the adverse effects of myocardial I/R. Moreover, there are unavoidable situations in transplant surgery in which a longer cold ischaemic period is required, therefore strategies to improve donor heart preservation after longer ischaemic periods are necessary. Clinical studies exploring ischaemic time and long-term posttransplant survival have reported an inverse relationship between the two [5] .
Poly(ADP-ribose) polymerase (PARP) is one of the abundant proteins in the nucleus. Under physiological conditions it is involved in the regulation of many cellular processes, such as the expression of various proteins implicated in the inflammation process at the transcriptional level (including inducible nitric oxide synthase, intracellular adhesion molecule (ICAM)-1, cyclooxygenase-2), the regulation of replication and differentiation, the DNA repair and maintaining genomic integrity [6] . Under pathological conditions, such as excessive DNA damage following oxidative stress, the overactivated nuclear enzyme PARP uses nicotinamide adenine dinucleotide (NAD + ) as a substrate, and it catalyzes the transfer of ADP-ribose units to target proteins. This results in the depletion of cellular NAD + pools, the inhibition of glycolysis and mitochondrial respiration, and ultimately in the reduction of intracellular ATP and other high-energy phosphates in the reperfused heart [7] . Excessive activation of PARP also strongly upregulated the expression of the nuclear transcription factor activator protein (AP)-1 and AP-1-dependent genes, including ICAM-1 [8] . All together, the overactivation of PARP has been identified as a key pathway of myocardial reperfusion injury [9] . Thus, the inhibition of PARP prevents myocardial cellular energy deficits, improves myocardial contractility, attenuates proinflammatory gene/mediator expression and recruitment of neutrophils into reperfused myocardium, and decreases cardiomyocyte and endothelial cell necrosis [10] . In previous studies, our research group has reported beneficial effects of pharmacologic PARP inhibition upon cardiovascular diseases associated with increased nitro-oxidative stress, such as endothelial dysfunction induced by ROS [11, 12] or by irradiation [13] , neointima formation [14] , atherosclerosis [15] , or cardiovascular ageing [16] . In experimental models of canine cardiopulmonary bypass [17] and in rat heart transplant [7] studies, we have shown that hypothermic cardiac arrest and reperfusion lead to a significant PARP activation and to a loss of cellular energy pools. Beneficial effects of a PARP deficiency [18] or PARP inhibitors [19] on functional contractile parameters and on highenergy phosphates after global myocardial I/R were also reported.
Taking this into consideration, we assessed the hypothesis that a pharmacologic PARP inhibition, by a water soluble PARP inhibitor with an isoindoline structure INO-1001 would allow an extension of cold preservation time with improved cardiac and endothelial function in our well-established rat model of heterotopic transplantation [20] . Additionally, we tested the effects of PARP inhibition on vascular graft responsiveness in normoxic and prolonged cold ischaemia/warm reperfusion conditions in an in vitro model of isolated rat thoracic aorta.
MATERIALS AND METHODS

Animals
Male Lewis rats (250-350g; Charles River, Sulzfeld, Germany) were housed in a room at 22 ± 2 C under 12-h light/dark cycles and were fed standard laboratory diet ad libitum. The rats were acclimatized for at least 1 week before experiments. All animals received humane care in compliance with the 'Principles of Laboratory Animal Care', formulated by the National Society for Medical Research, and the 'Guide for the Care and Use of Laboratory Animals', prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 86-23, revised 1996) . This investigation was reviewed and approved by the appropriate institutional review committees.
RAT MODEL OF HETEROTOPIC HEART TRANSPLANTATION
Surgical preparation of heart transplantation
The transplantations were performed in an isogenic Lewis to Lewis rat strain. The experimental model was described elsewhere [20] . Briefly, the donor rats were anaesthetized with a single intraperitoneal injection of xylazine (3 mg/kg) and ketamine (100 mg/kg). Cardiac arrest was induced by Custodiol (histidinetrypthophane-ketoglutarate) solution (Dr Franz Köhler, Chemie GmbH, Germany), and the superior and inferior caval veins and the pulmonary veins were tied en masse with a 4-0 single silk suture. Then, the heart was explanted and immediately placed into cold Custodiol solution (4 C) for 4 h or 8 h according to assigned group.
The recipient rats were anaesthetized and then heparinised (400 IU/kg). The aorta and the pulmonary artery of the donor heart were anastomosed end to side to the abdominal aorta and the vena cava of the recipient rat, respectively. We needed 30 min to complete the anastomoses during heart transplantation. This additional ischaemic period after the storage period has already been taken into consideration. To minimize variability between experiments, the duration between explantation and reperfusion has been standardized to 1 h. During the suturing process it is not possible to actively maintain a defined temperature due to the recipient rat's body temperature. After completing the anastomoses, the heart was reperfused with blood in situ for 1 h.
Experimental groups
Rats were randomly divided into four groups: (a) control 4 h: donor hearts were subjected to 4 h cold ischaemic preservation and transplanted; recipient rats received 5% saline vehicle during reperfusion; (b) control 8 h: donor hearts were submitted to 8 h cold ischaemic preservation and transplanted; recipient rats received 5% saline vehicle during reperfusion; (c) INO-1001 4 h: donor hearts were submitted to 4h cold ischaemic preservation and transplanted; recipient rats received INO-1001 during reperfusion; (d) INO-1001 8 h: donor hearts were submitted to 8 h ischaemic preservation and transplanted; recipient rats received INO-1001 during reperfusion. A short intravenous infusion of 5% glucose solution vehicle or INO-1001 (5 mg/kg) through the inferior vena cava was started immediately prior to releasing the aortic clamp and continued during the first 5 min of the reperfusion period. Six male Lewis donor-and six recipientrats were used in each group.
Functional measurement in the graft
One hour after transplantation a small incision was made into the apex using a 0.9 mm cannula. A 3F latex balloon catheter (Edwards Lifesciences Corporation, Irvine, CA, USA) was then introduced into the left ventricle via this incision. Before starting the measurement and inflating the balloon, we waited until no arrhythmias, that could disturb the measurement, occurred. This period usually lasted 1-5 min. The latex balloon was only inflated during the measurement and was deflated between each measurement. Heart rate, left-ventricular (LV) systolic pressure, LV end-diastolic pressure, maximal slope of the systolic pressure increment dP/dt max and maximal slope of the diastolic pressure decrement dP/dt min were measured by a Millar micromanometer (Millar Instruments, Houston, TX, USA) at an intraventricular volume of 80 ml, and were analysed offline with PVAN 3.6 software (Millar Instruments, Houston, TX, USA). Thereby the provided LV end-diastolic pressure values were assessed at defined preload conditions, independent from the LV venous drainage. The besian coronary venous flow was neglectable in relation to the balloon volume. To measure coronary blood flow, an ultrasonic flow meter (Transonic Systems Inc., Ithaca, USA), with a diameter of 1 mm, was mounted on the ascending aortic segment of the donor heart, between the arterial anastomosis and the sinotubular junction. Thereby the ultrasonic flow probe measures the retrograde flow in the donor aortic segment from the aorta of the recipient towards the coronary arteries of the transplanted heart, which is equal to coronary blood flow in the present nonejecting transplant model. Endothelium-dependent vasodilator acetylcholine (ACh) was administered as a single bolus injection (1 nM, 0.2 ml) into the donor aorta using a small cannula inserted through the apex of the donor heart. ACh reached the coronaries of the graft via the aortic root. The abdominal aorta of the recipient was distally clamped during the injection to avoid systemic effects.
RAT MODEL OF ENDOTHELIAL DYSFUNCTION INDUCED BY LONG-TERM COLD ISCHAEMIC STORAGE AND REPERFUSION
Preparation and conservation of aortic rings
Rats were anesthetized with sodium pentobarbital (60 mg/kg). The descending thoracic aorta was carefully removed and quickly transferred to cold (+4 C) Krebs-Henseleit solution (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 1.77 mM CaCl 2 , 25 mM NaHCO 3 , 11.4 mM glucose; pH = 7.4). The aorta was prepared and cleaned from periadventitial fat and surrounding connective tissue, and it was then transversely cut into 4-mm width rings.
Experimental groups
Isolated thoracic aortic rings (n = 8-16 rings from N = 4-6 rats in each group) were stored for 24 h at 4 C in closed, air-free tubes filled with Custodiol. After 24 h conservation, the rings were reoxygenated for 75 min at 37 C in organ baths containing 30 ml Krebs-Henseleit supplemented with 5% glucose solution vehicle (Custodiol 24 h group) or the PARP-inhibitor INO-1001 (final concentration of INO-1001 in the organ bath 1 mM) (Custodiol 24 h + INO-1001 group). Aortic rings in the control group did not undergo cold ischaemic storage, but were immediately mounted in the organ bath.
In vitro organ bath experiments
The aortic rings were mounted on stainless steel hooks under 2 g of resting tension in individual organ baths (Radnoti Glass Technology, Monrovia, CA, USA), containing 30 ml of KrebsHenseleit solution. The solution was gassed continuously with 95% O 2 -5% CO 2 and warmed to 37 C. Special attention was paid during the aortic dissection to avoid damaging the endothelium. The tissue was equilibrated for 60 min. During this period, the tension was periodically adjusted to the desired level, and the Krebs-Henseleit solution was changed every 30 min as a precaution against interfering metabolites [21] . Potassium chloride (KCl) was used in these experiments to test viability and prepare the vessel rings for stable contractions with reproducible doseresponse curves to other vasoactive agents. At the beginning of each experiment, maximal contraction forces to KCl (80 mM) were determined and aortic rings were washed until the aforementioned resting tension was again obtained. An a-adrenergic receptor agonist, phenylephrine (PE, 10 -6 M), was used to precontract the rings until a stable plateau was reached, and the relaxation responses were examined by adding cumulative concentrations of endothelium-dependent vasorelaxant, ACh (10 -9 -10 -4 M), and endothelium-independent dilator, sodium nitroprusside (SNP, 10 -10 -10 -5 M). The relaxation is expressed as percentage of contraction induced by PE.
Chemical reagents, preparation and application INO-1001, an indeno-isoquinolinone-based poly(ADP)-ribose polymerase inhibitor, was provided by Inotek Pharmaceuticals (Beverly, MA, USA). For in vivo application it was dissolved in 5% glucose solution and administered intravenously at the dose of 5 mg/kg. For in vitro application it was used at a concentration of 1 mM. The doses of INO-1001 applied both in the in vivo and in vitro studies are based on previous publications [11, 22, 23] , and the in vivo doses (i.p.) applied correspond to the in vitro concentration used.
Statistical analysis
All data are expressed as mean ± standard error of the mean (SEM). Means between groups were compared by one-way analysis of variance with Bonferroni correction for multiple comparisons. The statistical analysis of graft survival (i.e. number of rats with functioning graft) data was performed using SPSS 22.0 software (SPSS Inc., Chicago, Illinois). Kaplan-Meier analysis with log rank test was used to assess the difference in survival between the control group and substance group at different cold ischaemic times. A value of P < 0.05 was considered indicative of significance.
RESULTS
In vivo effects of INO-1001
INO-1001 improves LV systolic and diastolic function in the graft
Treatment with INO-1001 led to a significantly better recovery of dP/dt max and LV systolic pressure (Control 4 h 75 ± 4 vs INO-1001 4 h 92 ± 6 mmHg; Control 8 h 73 ± 6 vs INO-1001 8 h 94 ± 7 mmHg; P < 0.05 corresponding control) of grafts submitted to 4 and 8 h ischaemia (Fig. 1A) . Furthermore, INO-1001 administration significantly decreased LV end-diastolic pressure of grafts submitted to 8 h of ischaemia compared to the corresponding control (Fig. 1B) . There was no significant difference in heart rate among the experimental groups (Control 4 h 287 ± 35 vs INO-1001 4 h 309 ± 41 beats/min; Control 8h 307 ± 29 vs INO-1001 8 h 314 ± 31 beats/min, P > 0.05).
INO-1001 improves in vivo coronary vascular function in the graft
Coronary blood flow was significantly higher in the INO-1001 4 h and 8 h groups in comparison to controls ( Fig. 2A) . Endotheliumdependent vasorelaxation, after acetylcholine, was significantly better in the INO-1001 groups than in the vehicle-treated transplant groups (Fig. 2B) .
INO-1001 improves graft survival rate
Although using donor hearts with 4 h ischaemia did not have an impact on graft survival (i.e. a functioning graft at the time of measurement of cardiac function), a longer ischaemic time of 8 h showed a tendency toward a decreased graft survival rate in the vehicle-treated rats (Control 4 h: 6/6 vs Control 8 h: 3/6; P = 0.056). There was no death of the grafts in the INO-1001 administrated animals regardless of the cold ischaemia duration (INO-1001 4h: 6/6 and INO-1001 8 h: 6/6).
In vitro effects of INO-1001
Endothelium-dependent vasorelaxation of the aortic rings acetylcholine-induced, endothelium-dependent, NO-mediated vasorelaxation when compared to the Custodiol 24 h group (Fig. 3A) .
Endothelium-independent vasorelaxation of the aortic rings Figure 3B shows concentration-dependent relaxations induced by 10 2 10 M-10 2 5 M SNP, an endothelium-independent vasodilator. In contrast to ACh, maximal relaxation in response to SNP did not significantly differ among the different experimental groups.
DISCUSSION
In the present investigation, we tested the hypothesis that targeting the inhibition of PARP activation would allow an extension of cold preservation time and protect the graft against I/R injury in a rat heart transplantation model. We have shown that PARPinhibition by INO-1001 resulted in a better functional recovery of grafts after cardioplegic arrest, prolonged hypothermic storage and warm reperfusion. Furthermore, pharmacological PARP inhibition in an in vitro model of vascular dysfunction, induced by long-term cold ischaemic storage and reperfusion, effectively preserved endothelial function.
Heart transplantation is now the therapy of choice for terminal heart failure. However, the discrepancy between waiting lists and performed operations increased dramatically due to increasing demand, and the shortage of suitable organs. To optimize the use of the limited resource, long distance procurement may increase the available donor pool. However, gathering organs from distant locations results in a prolongation of donor ischaemic times. Under these circumstances better organ preservation solutions/methods are required, and PARP INO-1001 is an interesting candidate to reduce post-transplant organ dysfunction. Prolonged ischaemia prior to implantation into the recipient is the most decisive factor of primary graft dysfunction occurring in the immediate post-operative period after heart transplantation [1] . Therefore, fast recovery of myocardial function is essential for the success of cardiac transplantation, and myocardial protection plays a key role in preserving myocardial function after surgery. Considering this, we evaluated the effects of INO-1001 in the early phase, as early graft dysfunction is the main determinant of the long-term outcome following heart transplantation. This is the first study showing that the inhibition of PARP activation by INO-1001 permits an extended safe cold ischaemic time with improved graft LV systolic performance (as shown by increased dP/ dt max ) and passive diastolic function (as evidenced by decreased LV end-diastolic pressure). In line with these observations, we already demonstrated that PARP inhibitors may prevent PARP activation and myocardial dysfunction after 1 h of global myocardial I/R in rat cardiac transplant [7] , which was also confirmed by other authors [24] . During myocardial I/R the massive release of reactive oxygen and nitrogen species induces DNA damage, leading to cell necrosis and apoptosis. The excessive death of cardiomyocytes ultimately leads to cardiac dysfunction. The mechanisms underlying the cardioprotective action of PARP inhibition on the reperfused myocardium include greater preservation of myocardial high-energy phosphate stores, resulting in an improved energy status [7] . Previously, we have shown that myocardial high-energy phosphate content, especially ATP-content, as well as energy charge potential were preserved by PARP inhibition during heart transplantation [7] . Rapid recovery of ATP upon reperfusion following ischaemia is essential for cell survival after I/R injury. Of course, irreversibly damaged myocytes will not completely replenish ATP [25] . We do not have evidence for this point, as the high-energy phosphate content was not measured in the present study. Other mechanisms of PARP inhibition include suppression of proinflammatory pathways and regulation of neutrophil trafficking. As a result INO-1001 may regulate the expression of adhesion molecules and the maintenance of endothelial integrity [6] , and it may decrease cardiomyocyte and endothelial cell necrosis [10] . The role of PARP-1 on apoptosis in an acute regional myocardial I/R injury model has also been investigated. Zingarelli et al. demonstrated that the inhibition of PARP-1 during reperfusion (after 30 min left anterior descending coronary artery occlusion) provides cardioprotection and that an amelioration of damage is associated with a reduction of myocardial apoptotic cell death [26] . Additionally, in the absence of functional PARP-1, cardioprotection is associated with reduced nuclear factor kappa B (NFkB) activation and marked alterations of apoptotic regulators' gene expression [26] . Furthermore, improvement of in vivo coronary vascular function may modulate myocardium's contractile characteristics. All together, these mechanisms could be, in part, involved in the improved cardiac functional recovery during reperfusion after PARP inhibition post longer ischaemic times.
Vascular grafts are essential therapeutic materials for bypass surgery. The healthy vascular endothelium plays a key role in providing the proper vascular homeostatic balance through a variety of regulatory substances. The release of endothelium-derived relaxing factors, such as nitric oxide (NO), prostacyclin (PGI 2 ), and endothelium-derived hyperpolarizing factor (EDHF), as well as vasoconstrictor factors such as endothelin, superoxide anion and thromboxane underlie this activity. The prolonged hypothermic storage of blood vessels without adequate protection may lead to acute endothelial dysfunction and endothelial cell activation, leading to leucocyte adhesion to the vascular wall, platelets aggregation, smooth muscle proliferation and increased vasoconstriction [27] . Endothelial dysfunction is defined as the impairment of the physiological ability of the endothelium to dilate fully in response to vasodilatory stimuli such as shear stress or ACh, and as the impairment of fibrinolytic and anti-aggregating activities. Therefore, new therapeutic strategies are required to protect the endothelial cell integrity of vascular grafts under conditions of increased oxidative stress, such as prolonged I/R, to combat vascular dysfunction and to improve the long-term survival of heart transplant recipients. In the present study, we also investigated the effects of PARP inhibition in an in vitro experimental model of vascular dysfunction, induced by long-term cold ischaemic storage followed by warm reperfusion. The endothelial function was measured in thoracic aortic segments by analysing the concentration-response curves to ACh in rings precontracted with PE. We demonstrated that an exposure of rat aortic rings to prolonged cold ischaemia followed by warm reperfusion in vitro resulted in endothelial dysfunction, which can be prevented by the inhibition of PARP (treatment of aortic rings with INO-1001). The endothelium plays a major role in coronary blood flow regulation. Improvement of vascular function (based on our in vitro experiment) can, in part, be responsible for enhanced myocardial protection in vivo, secondary to improved coronary blood flow by INO-1001 after myocardial I/R. Additionally, our functional results show no impairment of the relaxation apparatus in the smooth muscle cells, examined by endothelium-independent relaxation to SNP. Previous data from our group has demonstrated that PARP activation contributes to the pathogenesis of hydrogen peroxide and hypochlorite induced endothelial dysfunction, which can be prevented by PARP inhibitors [11, 12] . Furthermore, pharmacologic PARP inhibition also prevents the development of endothelial dysfunction in vascular rings exposed to another reactive nitrogen species, peroxynitrite [28] .
In conclusion, we demonstrated favourable effects of a pharmacologic PARP inhibition activation on graft dysfunction and endothelial injury that is caused by prolonged cold myocardial ischaemia/warm reperfusion. From a clinical perspective, our data may provide a better strategy for reducing or preventing I/R injury, thereby increasing safe cold ischaemic preservation time during cardiac transplantation surgery. However, further detailed studies are required to reveal the molecular mechanisms underlying INO-1001's protective effects on cardiac and vascular protection.
Study Limitations
There are some limitations to our study. This heterotopic model in rats was selected to be a suitable model for evaluating global I/R injury for short-term studies of heart transplantation. The ventricles are perfused via coronary circulation, but they do not eject, which on one hand allows a faster recovery from ischaemia/reperfusion injury, and on the other hand leads to time-dependent mechanical deterioration and atrophy. Nevertheless, a detailed characterization of this model has shown that major deterioration does not occur within the first 24 h after transplantation [29] .
